Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMVZ2FG)

• Drug Name: TAK-500 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Aggressive cancer	2A00-2F9Z	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMVZ2FG

Molecule-Related Drug Atlas

Drug(s) Targeting Stimulator of interferon genes protein (TMEM173)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ADU-S100	DM8HBUI	Head and neck cancer	2D42	Phase 2	[2]
ADU- S100	DMM6B2Y	Head and neck cancer	2D42	Phase 2	[3]
MK-1454	DMEDITW	Squamous head and neck cell carcinom	2D60.0	Phase 2	[4]
IMSA101	DM43ICH	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[5]
BMS-986301	DMM3DBU	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
MK-2118	DMKNH8B	Lymphoma	2A80-2A86	Phase 1	[7]
SB 11285	DMZ9YWG	Head-neck squamous cell carcinoma	2D60.0	Phase 1	[8]
E7766	DM8TU5R	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]
GSK3745417	DMRYNJD	Solid tumour/cancer	2A00-2F9Z	Phase 1	[10]
TAK-676	DMCKF5J	Solid tumour/cancer	2A00-2F9Z	Phase 1	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Stimulator of interferon genes protein (TMEM173)	TTT402Y	STING_HUMAN	Agonist	[1]

References

• [1] ClinicalTrials.gov (NCT05070247) An Open-label, Dose Escalation and Expansion, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of TAK-500, a Novel Stimulator of Interferon Genes Agonist, as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Select Locally Advanced or Metastatic Solid Tumors. U.S.National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Magnitude of Therapeutic STING Activation Determines CD8 + T Cell-Mediated Anti-tumor Immunity. Cell Rep. 2018 Dec 11;25(11):3074-3085.e5.
• [4] National Cancer Institute Drug Dictionary (drug name MK1454).
• [5] Clinical pipeline report, company report or official report of ImmuneSensor Therapeutics.
• [6] Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy. J Clin Med. 2020 Oct 16;9(10):3323.
• [7] National Cancer Institute Drug Dictionary (drug name ML2118).
• [8] Clinical pipeline report, company report or official report of F-star Therapeutics.
• [9] E7766, a Macrocycle-Bridged Stimulator of Interferon Genes (STING) Agonist with Potent Pan-Genotypic Activity. ChemMedChem. 2021 Jun 7;16(11):1740-1743.
• [10] National Cancer Institute Drug Dictionary (drug name GSK3745417).
• [11] National Cancer Institute Drug Dictionary (drug name TAK676).